Asthma Clinical Trial
Official title:
Using the Telephone to Improve Care in Childhood Asthma
Asthma is the most common chronic disease of childhood and a major cause of morbidity in the
United States. If asthma symptoms are controlled, a child with asthma can stay well and lead
a normal life. Daily use of inhaled steroids controls symptoms and reduces morbidity and
emergent health care utilization in children with persistent asthma, and is safe for
long-term use. However, inhaled steroids are underused in community asthma care.
The Telephone Asthma Program (TAP) is a series of brief, telephone calls with a trained
coach to help the parent manage the child's asthma care. The coach will teach
self-management skills, help the parent to use the child's asthma medicines effectively,
provide support and remind the parent to go for follow-up care with the pediatrician. We
hypothesized that the Telephone Asthma Program will reduce the incidence of acute
exacerbations of asthma that require emergent care, improve the quality of life of children
with asthma and their parents, and increase the daily use of inhaled steroids in children
with persistent asthma. We evaluated the Telephone Asthma Program in a randomized controlled
trial involving 362 children aged 5 to 12 years old cared for by community pediatricians.
Eligible children were randomized to the TAP program or usual care by their pediatrician.
Asthma morbidity is largely preventable with effective maintenance care. National guidelines
recommend 1) daily treatment with inhaled corticosteroids (ICS) to prevent asthma symptoms
and activity limitations, minimize acute exacerbations and maintain normal lung function; 2)
early intervention guided by a written Asthma Action Plan for worsening symptoms;3) a
partnership between the primary care provider, the patient and their family to develop
shared treatment goals, select an appropriate treatment plan, resolve asthma-related
concerns, and provide support for day-to-day care, and 4) periodic assessments (every 1 to 6
months) by the physician to monitor asthma control and assess if the goals of therapy are
being met, with asthma self-management education provided at diagnosis and reinforced at
every opportunity. Despite widespread dissemination of these guidelines, under-use of
controller medications is pervasive, home management of an acute exacerbation is often
delayed and inadequate, and only 50% of asthmatic children report maintenance care visits
twice a year. Most primary care pediatricians do not provide education about use of
preventive treatments or self-management behaviors citing lack of confidence in their
ability to effect change, logistical issues such as lack of time, educational materials,
support staff, and inadequate reimbursement as significant barriers to these activities.
Practical, efficient interventions to improve maintenance asthma care in office-practice are
needed.
In response to complaints from community pediatricians in our practice-based research
network that few children with persistent asthma used their controller medications as
prescribed we collaborated with local asthma experts and the telephone triage service at our
children's hospital to develop and evaluate a 12-month telephone-coaching program to provide
education and support to parents to improve asthma self-management for their children. The
Telephone Asthma Program (TAP) was provided in addition to usual care, and was evaluated in
a randomized controlled trial (RCT).
The TAP program was based on the Transtheoretical Model of Behavior Change developed by
James Prochaska. This model postulates a series of 5 ordered stages of readiness to change
to a desired behavior (Precontemplation, Contemplation, Preparation, Action and
Maintenance). The desired behaviors for TAP were: 1) using controller medications as
prescribed, 2) administering rescue medications at the child's first signs of an asthma
exacerbation, 3) having an up-to-date asthma action plan readily available for all who may
need it, and 4) having a collaborative relationship with the child's PCP that included
regular asthma check-up visits at least every 6 months. Our goal was that all 4 behaviors
would be addressed by the coach for each parent throughout the 12-month program period.
Guided by computerized telephone protocols the coach provided tailored care advice
appropriate for the parent's stage of readiness for behavior change. In this way, the coach
could provide education and support to help the parent to provide effective asthma care at
home for their child, and supplement the care provided by the physician.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|